Emotion Regulation Training to Reduce Cardiovascular Disease Risk Among Depressed Young Adults in Southern Mississippi

Sponsor
University of Southern Mississippi (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05425290
Collaborator
(none)
25
1
1
12
2.1

Study Details

Study Description

Brief Summary

The proposed study will investigate the utility of a single-session emotion regulation training to reduce CVD risk among young adults diagnosed with MDD living in Southern MS. Using an single-arm, non-randomized design, young adults aged 18-29 will undergo a single-session emotion regulation skills training. Before and immediately after the skills training session, participants will supply several biological metrics tied to CVD risk: resting HRV, inflammation (measured via c-reactive protein [CRP]), and blood pressure. Participants will provide the same biological metrics at a one-week follow-up visit to assess short-term sustained gains following the single-session intervention and complete a 7-day ecological momentary assessment (EMA) of their daily emotion regulation skills use and depressive symptoms between these two visits.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Single-session emotion regulation training
N/A

Detailed Description

Cardiovascular disease (CVD) is a leading cause of death in Mississippi, accounting for over a third of deaths within the state. Mississippians face numerous health disparities that enhance disease risk throughout our community. In addition to behavioral factors, several notable biological markers enhance risk for CVD including low resting heart rate variability (HRV), high blood pressure, and inflammation. In Mississippi, an estimated 20.9% of adults meet criteria for depression. Adults experiencing depressive disorders experience high rates of emotion dysregulation, and psychological interventions that include emotion regulation training components are highly efficacious in reducing psychological and physical symptoms associated with depression. Depression, particularly major depressive disorder, is routinely linked with enhanced CVD risk. Understanding and intervening on the relationship between CVD risk factors and depression in young adulthood offers potential to prevent exacerbation of risk later in life. This pilot study will investigate the utility of a single-session emotion regulation training to reduce CVD risk among young adults living in Southern Mississippi who are diagnosed with major depressive disorder (MDD). The study aims are to: 1) examine whether the single-session emotion regulation training promotes changes in biological risk factors for cardiovascular disease immediately following the training and at a 1-week follow-up visit; 2) to assess whether the single-session emotion regulation training reduces depressive symptoms among research subjects; and 3) to test whether use of emotion regulation skills learned during the training in the week following the intervention session promotes greater changes in cardiovascular disease risk factors. Using a lab-based experimental intervention design, young adults will undergo a single-session emotion regulation skills training. Before and after the skills training session, research subjects will supply several physiological metrics tied to CVD risk: resting HRV, c-reactive protein (CRP) levels, and blood pressure. Subjects will provide the same biological metrics at a one-week follow-up visit to assess short-term sustained gains following the single-session intervention. Results from this study offer potential to reduce emotion regulation difficulties associated with major depression, reduce CVD risk factors among young adults in Mississippi, and advance our knowledge of how psychological interventions can improve both psychological and physical risk factors for chronic health conditions among young adults, potentially buffering depression's long-term health impact.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Emotion Regulation Training to Reduce Cardiovascular Disease Risk Among Depressed Young Adults in Southern Mississippi: A Single-Session Design
Anticipated Study Start Date :
Aug 15, 2022
Anticipated Primary Completion Date :
Jun 15, 2023
Anticipated Study Completion Date :
Aug 14, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Arm

Behavioral: Single-session emotion regulation training
The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.

Outcome Measures

Primary Outcome Measures

  1. Change in Diastolic Blood Pressure [Change from prior to the single-session emotion regulation training to immediately after and 1-week after]

    Diastolic blood pressure will be measured prior to the training, immediately afterwards, and during the 1-week follow-up visit

  2. Change in Systolic Blood Pressure [Change from prior to the single-session emotion regulation training to immediately after and 1-week after]

    Systolic blood pressure will be measured prior to the training, immediately afterwards, and during the 1-week follow-up visit

  3. Change in Resting Heart Rate Varability (HRV) [Change from prior to the single-session emotion regulation training to immediately after and 1-week after]

    Resting heart rate variability (HRV) will be measured prior to the training, immediately afterwards, and during the 1-week follow-up visit

  4. Change in C-reactive protein (CRP) [Change from prior to the single-session emotion regulation training to immediately after and 1-week after]

    C-reactive protein (CRP) will be measured prior to the training, immediately afterwards, and during the 1-week follow-up visit

  5. Change in Center for Epidemiological Studies - Depression Scale (CESD) [Change from prior to the single-session emotion regulation training to immediately after and 1-week after]

    Depressive symptoms will be assessed using the CESD prior to the training, immediately afterwards, and at the 1-week follow-up visit. Depressive symptoms will also be assessed during the EMA assessment period.

Secondary Outcome Measures

  1. Change in Emotion Regulation Questionnaire, Reappraisal subscale (ERQ-R) [Change from prior to the single-session emotion regulation training to immediately after and 1-week after]

    Reappraisal Skills will be measured by the ERQ-R and assessed prior to the training, immediately afterwards, and at the 1-week follow-up visit. Reappraisal skills will also be assessed during the EMA assessment period.

  2. Change in Experiences Questionnaire - Decentering (EQ-D) [Change from prior to the single-session emotion regulation training to immediately after and 1-week after]

    Decentering skills, measured by the EQ-D, will be assessed prior to the training, immediately afterwards, and at the 1-week follow-up visit. Decentering skills will also be assessed during the EMA assessment period.

  3. Change in Difficulties with Emotion Regulation Scale (DERS) [Change from prior to the single-session emotion regulation training to immediately after and 1-week after]

    Emotion Dysregulation, measured by the DERS, will be assessed prior to the training, immediately after, and at the 1-week follow-up visit.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 29 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Men and women ages 18-29

  2. Able to speak and read English

  3. Outpatient at the time of participation

  4. Able to provide informed consent

  5. Stable medications for 30 days or more

  6. Appropriate diagnoses:

  • Meets diagnostic criteria for current major depressive disorder
Exclusion Criteria:
  1. Not fluent in English

  2. Not able to provide informed consent

  3. Active suicidal ideation

  4. Presence of autoimmune and/or inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis)

  5. Ongoing use of steroids (if use of steroids is temporary, individuals are eligible to participate 30 days after termination)

  6. Medication change in the past 30 days (individuals are eligible to participate 30 days after a medication change and may take advantage of delayed scheduling)

  7. Meets diagnostic criteria for a schizophrenia-spectrum disorder, substance use disorder, and/or bipolar disorder

  8. Presence of a cardiovascular disease (e.g., hypertension) or prescribed cardiovascular medications (e.g., beta blockers, blood pressure medication)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Southern Mississippi Hattiesburg Mississippi United States 39406

Sponsors and Collaborators

  • University of Southern Mississippi

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Southern Mississippi
ClinicalTrials.gov Identifier:
NCT05425290
Other Study ID Numbers:
  • USMississippi
First Posted:
Jun 21, 2022
Last Update Posted:
Jun 21, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 21, 2022